Materialise reports stable 2025 financial results with marginal revenue increase
Q4 year-on-year up 6.8%, with company's medical sector the standout performer at 15% YoY growth
Materialise NV, a Belgian AM software and service provider which trades on the NASDAQ, has reported its 2025 financials, and closed the fourth quarter of the year with total revenue of €70.2 million ($82.7m), up 6.8% from €65.7m ($77.4m) in the same period a year earlier.
The company’s Materialise Medical segment drove that growth, generating €37m ($43.6m) in quarterly revenue — a 16.3% increase year-over-year for the same period, and a new quarterly record for the unit.
For the full financial year, the total revenue of €267.6m ($315.4m) remained stable compared to 2024 (€266.7m / $314.4m), with the medical sector again a significant area of growth at 15.4% YoY – a trend which was indicated at the midway point of last year. That increase was offset by lower revenues in Materialise’s manufacturing segment and “unfavourable foreign exchange effects”.
“In the final quarter of 2025, we reached a major milestone with our successful Euronext listing and the announcement of a strategic share buyback program. These steps clearly demonstrate our commitment to delivering long-term shareholder value” stated CEO Brigitte de Vet-Veithen.
“We achieved nearly 7% revenue growth and delivered a substantial improvement in operational profitability compared to the fourth quarter of 2024. Our Materialise Medical segment continues to lead the way, achieving another quarterly revenue record and sustaining its double-digit growth path. Our Materialise Software segment maintained steady upward momentum, continuing to build on successive quarterly revenue increases throughout 2025.
“While our Materialise Manufacturing segment continued to be impacted by soft prototyping demand, its strategic transition towards series manufacturing led to key commercial wins in targeted aerospace and defense markets that we expect will contribute to our results in coming periods.
“Throughout the last quarter of 2025 we further executed focused cost control measures without compromising R&D investments. With €134m ($157.9m) of cash and cash equivalents on our balance sheet, an improved net cash position and consistently positive operating cash flow, we believe we are financially strong and well-positioned to further drive innovation and capture emerging market opportunities.”
Vet-Veithen confirmed that in 2026 the company expects its three sectors to evolve at different paces, with medical projected to continue its upward revenue trajectory.
The software segment will also complete its transition towards a cloud-based subscription business model this year, and further reinvest in “a broader AM software ecosystem covering end-to-end workflows”.
